Maintaining your independence in biotechnology

Mergers and acquisitions are regular events for biotechnology companies. I have often been asked if being acquired is a goal for biotechnology companies, and if it is seen as a ‘good’ or a ‘bad’ thing. The outlook on merging with another company, or being acquired, is really just a matter of timing. As I describe […]


Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues
Go to paperABSTRACT: Biopharmaceuticals and innovative therapeutic…


Biotechblog